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Abstract
Background: Staphylococcus aureus is a serious pathogen with high 
rates of complications. We aim to study the susceptibility and outcome 
of S. aureus infection.
Methods: A retrospective multicentre study conducted in three hos-
pitals, Amman-Jordan. Between June 2013 and March 2014 labora-
tory records were reviewed for culture-positive samples growing S. 
aureus, also, medical records for the patients were reviewed for the 
demographic data, predisposing conditions, vancomycin MIC level, 
and outcome. Inpatients and outpatients were included, a case was 
classified as either hospital-associated (HA), community-associated 
(CA), or healthcare-associated (HCA). Data were entered as excel 
sheets and were statistically analyzed using SPSS version 21.
Results: A total of 127 patient (46% MRSA) were culture-positive 
for S. aureus collected from different sources. Of these, eighty (63%) 
were inpatients. High resistance rates to non-β-lactam antimicrobials 
were recorded. Glycopeptides agents were the antibiotics of choice 
for the treatment of infections caused by MRSA strains. Complications 
rates were higher in patients with MRSA infections including mortality, 
whereas hospital stay was longer for patients infected with MSSA. 
Conclusion: Infection rates with MRSA were high among patients. 
There is a value for knowing vancomycin MICs for treatment of S. au-
reus and its implication for patients outcomes, though most outcomes 
were significantly worse due to MRSA infection.
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Introduction
Staphylococcus aureus is a serious pathogen and a 
leading cause of both community- and healthcare-
associated infections. Several factors may predispo-
se patients to the development of 
S. aureus infections such as intensive care units 
(ICUs) stay, long-term care facility residents, surgi-
cal patients, immunocompromised conditions, pa-
tients on hemodialysis, and various invasive proce-
dures [1-2]. According to some healthcare systems, 
S. aureus was the second most common isolate, 
accounting for 20% of cases, and a prospective 
analysis in 49 hospitals in the united states bet-
ween 1995-2002, reported that the proportion of 
MRSA increased from 22% in 1995 to 57% in 
2001 [3]. Among patients consecutively admitted 
in 1993 to the adult intensive care unit (ICU) in 
Jordan University Hospital in Amman-Jordan, the 
most frequent species isolated was S. aureus [4]. 
A single center study conducted in Jordan hospi-
tal over a period of 3-year, found S. aureus the 
third most common blood isolate in the ICU after 
coagulase-negative staphylococci and E. coli, and 
accounting for 9.8 percent of cases [5]. Nonethe-
less, there has been in the mid-1990s an increase 
in the number of MRSA infections among patients 
who lacked proper health care exposure. This in-
crease has been associated with the recognition of 
a different MRSA strains, such as community-as-
sociated MRSA (CA-MRSA),and these strains have 
rapidly spread in the world causing infections in 
the general population [6 -12]. In an analysis of 132 
cases of MRSA bloodstream infections in patients 
admitted to a hospital in Atlanta- USA in 2004, 
molecular typing studies demonstrated that 34% 
of isolates were CA-MRSA, which was genetica-
lly distinct from the traditional strains HA-MRSA 
[13]. HA-MRSA strains carry a relatively large sta-
phylococcal chromosomal cassette mec (SCCmec) 
belonging to type I, II, or III. These cassettes con-
tain mecA gene, which is nearly universal, they are 
often resistant to many classes of antimicrobials. 
Also, CA-MRSA isolates carry SCCmec type IV or 
V, though smaller elements and presumably mo-
bile, but they are resistant to fewer non-β-lactam 
classes and frequently carry PVL genes [14]. Pa-
tients infected with MRSA strains need more care 
and have a poorer prognosis. Several studies have 
demonstrated increased mortality among patients 
infected with MRSA compared to MSSA infection 
[15-17]. 
This study aims to identify S. aureus susceptibility 
to vancomycin and the outcomes of its infection on 
patients in Jordan.
Materials and Methods
Study Design and Settings
This is an observational multicenter study included 
three private hospitals (Arab Medical Center, Al-Kha-
lidi Hospital and Medical Center, and the University 
of Jordan hospital, Amman, Jordan. The study was 
approved by the institutional review board (IRB) in 
every hospital. Outpatients, and inpatients who had 
positive cultures of S. aureus were recruited over 
the period (June 2013 through March 2014). Re-
cords of the inpatients were reviewed, and patients 
were followed during hospitalization and after dis-
charge. A case report form was filled included the 
following items: patients’ demographic data; age, 
sex, weight, length of stay (LOS), admission loca-
tion; ICU, medical, surgical, gynecology and pedia-
tric. The chief complaint for admission, diagnoses, 
source of culture, infectious diagnosis, surgical pro-
cedures, previous antibiotic use, the antimicrobial 
susceptibility of S. aureus isolates, predisposing cli-
nical conditions and comorbidities, malignancy, ad-
ministration of steroids > 20 mg/day of prednisone 
use or its equivalent for more than 14 days prior 
to specimen culture, antineoplastic chemotherapy 
in the 3 months prior to culture collection, long-
term facility residence, indwelling catheters, intra-
venous drug use, diabetes mellitus, kidney disease, 
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hemodialysis, skin or soft tissue lesions, respiratory 
illness, surgery wound and surgery requiring more 
than 48 h of hospitalization in the 30 days prior 
to admission, invasive procedures including cardiac 
catheterization, arterial angiogram, upper endosco-
py, colonoscopy, bronchoscopy, tracheostomy, bone 
marrow aspiration, renal biopsy, hospitalization in 
the previous 12 months, and a history of previous 
MRSA infection and/or colonization. The patient's 
data about the use of antibiotics in the last three 
months and/or last week, frequent use of antibiotics 
prior vancomycin or other anti-MRSA agent expo-
sure were recorded.
Inclusion criteria
S. aureus culture-positive specimens from inpatients 
and outpatients were included. The isolated S. au-
reus were classified as HA, CA, and HCA. CA-S. 
aureus is considered if the first isolate was recove-
red within 48 h of hospitalization, and if obtained 
from an outpatient source or the isolate was reco-
vered within 48 h of hospitalization but believed to 
have had been incubating on admission, HCA cul-
tures were considered from patients that frequently 
need healthcare attention or invasive procedures, 
but not admitted e.g. hemodialysis patients (CDC 
Definition). Non-duplicate strains for S. aureus iso-
lates were considered. The outcome evaluated were 
vancomycin MIC distribution in relation to improved 
and discharged, discharged without improvement, 
switch to another antibiotic, relapse-progression, 
≤ 30-days readmission, infection-related readmis-
sion and, all cause of mortality among patients su-
ffering of S. aureus infection.
Identification of S. aureus
S. aureus was identified by the routine standard 
hospital microbiology laboratory procedure, methi-
cillin resistance was detected by the oxacillin and 
cefoxitin Kerby-Bauer disk diffusion, E-test (Retro 
C80TM, AB Biodisk, Sweden), or by VITEK 2 (bio-
Mérieux) for identification and antibiotic suscep-
tibility testing of gram-positive cocci was used to 
measure vancomycin MICs. Vancomycin susceptibi-
lity was defined according to The CLSI breakpoints 
(M100, Performance Standards for Antimicrobial 
Susceptibility Testing [18]); susceptible ≤ 2 mg/L, in-
termediate 4-8 mg/L, and concentrations ≥16 mg/
mL as resistant.
Statistical Analysis 
Statistical analyses were performed using the SPSS 
21 (Statistical Package for the Social Sciences, Ver-
sion 21, Inc. IBM Corporation, Chicago, IL, USA), 
and tables were initially analyzed by Microsoft Ex-
cel (Microsoft Corporation). All data were calculated 
by non-parametric analysis due to low numbers or 
groups. Numbers were transformed to frequencies 
and analyzed as relative frequencies among MSSA 
and MRSA covariates and outcomes. Wilcoxon Sign 
Rank test was used to analyze MRSA and MSSA 
paired differences for the covariates and outcomes. 
Regression analysis for the relation between MIC 
and the days for the length of hospital stay. Krus-
kal Wallis tests to the asses the difference among 
means. P-value < 0.05 was considered statistically 
significant.
Results
A total of 127 patients with their records for positi-
ve S. aureus cultures were recruited from the three 
hospitals in a 10-month period (June 2013-March 
2014). Males constituted 87 (69%) and females 40 
(31%). Out-patients were 47 (37%); infected with 
59.6% MSSA and 40.4% MRSA respectively, whe-
reas in-patients were 80 (63%); infected with 51.3% 
MSSA and 49.7% MRSA, respectively (Figure 1). 
The age of the patients was distributed into 
groups, they were almost similar in numbers, but 
less for the age group <20, elder inpatients were 
more than the other age groups, and the outpa-
tients elder age group were smaller in number. The 
total distribution of S. aureus susceptibility consis-
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Table 1.  Patients demographic features and charac-
teristics.
Demographic 
data
All 
Patients
Inpatients Outpatients
P
N % N % N %
Patients 
Number
127 100 80 63 47 37
Gender
Male 87 69 62 77.5 25 53.2
0.655
Female 40 31 18 22.5 22 46.8
Age (years)
< 20 19 14.96 6 7.5 13 27.7 0.144.
20 – 39 38 32.13 24 30 14 29.7
40–59 34 29.3 21 26.25 13 27.6
≥60 36 23.78 29 36.25 7 15
Distribution of S. aureus by susceptibility
MSSA 69 54.3 41 51 28 59.6
0.18
MRSA 58 45.7 39 49 19 40.4
Distribution of S. aureus 
by site
MSSAMRSA MSSAMRSA
Abdomen 0  0 0 0 0 0
0.423*
Blood 22  8 21 7 1 1
Bone 4  3 3 2 1 1
Respiratory 33  16 17 14 1 2
Skin 29  23 27 13 2 10
Urine 2  3 0 1 2 2
Others 9  4 2 0 7 4
P-values were calculated between the related groups i.e. MSSA 
versus MSSA and MRSA versus MRSA by Wilcoxon Sign Rank 
Test for inpatients and outpatients.
*P-value by the independent Kruskal Wallis Test. MSAA for the 
inpatients and outpatients and MRSA for the inpatients and 
outpatients were compared respectively.
Figure 1:  The distribution of patients with culture-
positive S. aureus samples.
127
patients 
 (Males 87, 69%) 
with S. aureus culture
MRSA
19 (40.4%)
MSSA
28 (59.6%)
MRSA
 41 (51.25%)
MSSA
39 (49.75%)
47 (37%)
Out-patients
80 (63%)
In-patients
MRSA: methicillin-resistant S. aureus. MSSA: methicillin-susceptible S. aureus.
ted of 69 (54.3 %) of MSSA and 58 (45.7%) of 
MRSA isolates; inpatients were 51% and 49% for 
MSSA and MRSA respectively. The outpatients were 
59.6%, 40.4%, respectively. S. aureus did not grow 
from the abdomen, it grew from blood of inpa-
tients. MSSA accounted for 75% of respiratory sam-
ple cultures which grew S. aureus from 49 patients 
(67.3% MSSA) and (32.7% MRSA), while skin grew 
52 isolates, with MSSA 55.8% and MRSA 44.2% 
(Table 1).
Demographic features were collected from 80 pa-
tients with S. aureus infection based on their oxacillin 
susceptibility. Comorbidities; (BMI>25, CVD, diabe-
tes, chronic kidney diseases, chronic respiratory di-
seases, and malignancy were significantly different 
in the distribution between MSSA and MRSA (P < 
0.05). However, there was no significant difference 
for smoking, CNS disorders and skin diseases (P > 
0.05). There was a significant difference between 
the numbers of MSSA and MRSA for the use of 
antimicrobials either within the prior 3 months or 
12 months of the study isolate (P < 0.05), and there 
were significant differences between both isolates 
based on the ward from which they were isolated 
(P < 0.05) (Table 2).
Both strains of S. aureus almost matched for 
their vancomycin susceptibility. The majority of 
MSSA isolates (20) and MRSA isolates (29) were 
in the range of 0.5-1.0 mg/L. There were 4 MSSA 
and one MRSA. 2 MSSA and 3 MRSA in the range 
MIC >1 -1.5 mg/L, and 1 MSSA, 2 MRSA in the 
range MIC > 1.5-2 mg/L and zero for both for the 
MIC >2 mg/L (Figure 2). Both strains were tested 
for susceptibilities based on the location of isola-
tion as inpatients or outpatients. After the exclu-
sion of the antimicrobials with zero susceptibility 
rates from MRSA like carbapenems and cephalos-
porines. In the MSSA there were statistically sig-
nificant differences (P < 0.05) between inpatients 
and outpatients with better inpatient susceptibility 
for clindamycin and erythromycin, but better out-
patient for quinolones, and TMP-SMX. For MRSA 
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Table 2.  Other demographic Features and charac-
teristics based on S. aureus oxacillin sus-
ceptibility.
Demographic data
All 
Patients
Inpatients
P
N % N %
S. aureus infections 
 (N = 80)
41 51 39 49
Type of infection acquisition
CA 6 2 0.014
HCA 20 26 0.000
HA 15 11 0.000
Type of infection acquisition
BMI >25 14 34 21 83.9 0.000
Tobacco smoking 16 39 16 41 1.00
CVD 17 41.4 15 38.5 0.000
Diabetes mellitus 18 44 20 51.3 0.000
Chronic kidney disease 10 24.4 11 28.2 0.002
Chronic respiratory illness 7 17 4 10.3 0.008
CNS disorders 3 7.3 2 5 0.083
Malignancy 9 21.9 2 5 0.003
Skin disease 5 12.1 5 12.8 1.00
Previous hospital admissions
Within prior 3 months 15 36.6 12 30.8
0.000
Within prior 12 months 32 78 28 71.8
Antibiotics within the last 3 
months
12 29 14 36 0.001
Length of hospital stay in 
days (range)
14.4 1-81 11 1-84 0.000
Hospital Service
ICU 9 21.9 12 30.7 0.003
Medical ward 14 34.1 10 25.6 0.000
Surgical ward 21 51.2 16 41 0.000
Pediatric ward 4 10 2 5 0.046
All-cause mortality 8 0.129 5 0.080 0.025
P value was tested by the Wilcoxon Sign Rank Test for the related 
MSSA - MRSA paired differences. CA: community-associated, 
HCA: healthcare-associated, HA: hospital-associated. CVD: 
cardiovascular disease, CNS: central nervous system, ICU: 
intensive care unit.
Figure 2:  The Relative distribution rates for pa-
tients with MSSA = 27 and MRSA = 
35, distributed according to the various 
Vancomycin MICs.
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there was a significant differences (P < 0.05) bet-
ween the inpatients and outpatients, better sus-
ceptibility rate in the outpatients for quinolones, 
gentamicin and rifampin, but better susceptibility 
rate among inpatients for erythromycin and TMP-
SMX (Figure 3).
S. aureus susceptibility to vancomycin, teicopla-
nin, tigecycline and rifampin was 100%. Cephalos-
porines, carbapenems, penicillin and piperacillin/
tazobactam were 0% active against MRSA. After 
exclusion of the antimicrobial agents with both 
100% susceptibility, and those with one agent 
with 0% susceptible for either strain from statisti-
cal analysis. Susceptibility differences for the other 
antimicrobial agents (quinolones, clindamycin, 
erythromycin, TMP/SMX and gentamicin) were 
significantly different in favor of MSSA (P < 0.001) 
(Figure 4)
The outcome rates for S. aureus were plotted as 
a strain specific relative frequency for MSSA and 
MRSA, the MICs relative frequency differences bet-
ween both strains for the range 0.5-1.0 mg/L The 
other MIC ranges were not considered for analysis 
for being zero or few in numbers. For all outcomes 
the difference in the relative frequencies for patients 
with MSSA or MRSA was evident pointing at a wor-
se MRSA outcome (P = 0.018), and for each outco-
me: improved and discharged (P = 0.008), relapse-
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Figure 3:  The Rates of MSSA and MRSA susceptibilities for several antimicrobial agents in inpatients 
and outpatients. For MSSA, there were statistically significant differences (P < 0.05) between 
inpatients and outpatients for Clindamycin and for erythromycin, quinolones, and TMP-SMX. 
For MRSA there were significant differences (P < 0.05) between the inpatients and outpatients 
for quinolones, gentamicin and rifampin, and for erythromycin and TMP-SMX. By 2-tailed 
Wilcoxon Sign Rank Test.
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Figure 4:  Antimicrobials Susceptibility Rates for S. 
aureus isolates from the outpatients.
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Figure 5:  The rates for patients with MSSA (20) 
and MRSA (29) for several measured 
outcomes. The Differences is measured 
by 2-taied Wilcoxon Sign Rank Test: 
improved and discharged (P = 0.008), 
relapse-progression (P = 0.001), ≤ 30-
days readmission (P = 0.005), infection 
related readmission (P = 0.008), and 
all-cause mortality (P = 0.025) but was 
not significant for: discharged without 
improvement (P = 0.083 ) and switch to 
another antibiotic (P = 0.083).
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Pip/Taz: piperacillin/tazobactam. Quinolones: Ciprofloxacin, levofloxacin. 
Carbapenems: Imipenem, meropenem, ertapenem. Cephalosporins: Cefazolin, 
Cefuroxime, Ceftriaxone, Cefepime.
progression (P = 0.001), ≤ 30-days readmission (P 
= 0.005), infection related readmission (P = 0.008), 
and all-cause mortality (P = 0.025) but was not sig-
nificant for discharged without improvement (P = 
0.083) and switch to another antibiotic (P = 0.083), 
(Figure 5).
Length of hospital stay was strongly associated 
with vancomycin susceptibility for MSSA, where it 
averaged 9.6 (n = 4, SD 5.86) when MIC was less 
than 0.5 mg/L, 14.06 days (n = 20, SD 20.79) for 
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MIC > 0.5-1 mg/L and 45 days (n = 2, SD 39.59) 
for MIC > 1-1.5 mg/L. Regression analysis showed 
perfect fit for the relation among MIC and length 
of hospital stay (R = 1, R2 = 1), Kruskal Wallace 
test showed no significant differences among the 
three length of hospital stay for the cited number 
of patients for each groups (P = 0.386).
Discussion
Our study showed that the MRSA rates among all 
isolates of S. aureus were 45.7%, these rates were 
lower than what was reported earlier by Frazee et 
al. (51%) and Kaplan et al. (76.4%) a decade earlier 
[7, 9] and 53.3% from Jordan [19]. The rates for the 
CA-MRSA (including HCA-MRSA) was 51.8%, con-
sistent with a previous study where it ranged 50.5-
79.5% [12]. Patients with MRSA were more likely 
to have a risk factor. In this study, 78% of MSSA 
cases and 71.8% of MRSA cases have a history of 
hospitalization in the last 12 months, those rates 
were not close to what was reported by Lescure, et 
al. which were 67% MSSA and 85% MRSA cases 
[20]. Comorbidities including BMI > 25, CVD, dia-
betes, chronic kidney diseases, chronic respiratory 
diseases, and malignancy were significantly higher 
in MRSA infected patients (P < 0.05). Smoking, CNS 
disorders and skin diseases were not different (P > 
0.05). There was a significant increase in the length 
of hospital stay and cost for patients with MSSA 
infection (P < 0.05), like a recent study by E. Y. Klein 
[21], possibly due to the relatively earlier and higher 
MRSA mortality rate in our patients (P = 0.025). 
Other studies found higher mortality rate associated 
with MRSA infection and longer hospital length of 
stay [16, 17, 22].
Our data showed that S. aureus was mostly con-
centrated in the susceptibility range (0.5-1 mg/L), 
with almost no distribution difference in the rela-
tive frequencies between MSSA and MRSA, and 
only fewer strains were in < MIC 0.5 mg/L and 
> MIC 1 mg/L. Though the standard of care in 
the treatment of MSSA are the penicillinase-resis-
tant semisynthetic penicillins or cephalosporines. 
Nevertheless, studies have shown that elevated 
vancomycin MIC for MSSA strains was associated 
with more treatment failures and mortality [23, 
24]. Eight patients (2 cancer patients) with MSSA 
infection were treated with vancomycin, 6/8 (75%) 
had a poor outcome, and the other patients were 
younger (31 and 6 years old). Vancomycin is con-
sidered suboptimal therapy for the treatment of 
MSSA infection compared to the anti-staphylococ-
cal β-lactams and is associated with the increased 
rates of treatment failure and high mortality rates. 
[25, 26] Despite the Infectious Diseases of Ame-
rica (IDSA) guidelines support using vancomycin 
for MRSA infections when are susceptible (MIC < 
2 mg/L), some studies and systematic reviews de-
monstrated treatment failure when patients were 
treated with vancomycin with MIC ≥ 1.5 mg/L. 
This is due to the difficulty in attaining the PK/PD 
target of AUC/MIC ≥ 400 with the clinical doses 
[27-33]. Furthermore, poorer prognosis was asso-
ciated with vancomycin MIC level of > 1 mg/dl 
[34]. Noteworthy, in our patients both MRSA and 
MSSA susceptibility to vancomycin showed almost 
similar MIC distribution, lucky enough the vast ma-
jority fell ≤ 1 mg/L, this would attain the PK/PD 
target when clinically achieving the serum trough 
levels of 15-20 mg/L. Also, our data demonstrated 
to some extent, that the higher S. aureus MIC 
for vancomycin, the longer the length of hospital 
stay for patients is noted, though regression and 
correlation among MICs and length of stay were 
perfect, but the difference between their means 
was not significant for the analyzed number of 
patients within each group (P = 0.386).
For several antimicrobials, MSSA and MRSA 
were compared respectively as inpatients and 
outpatients. For the MSSA, clindamycin and 
erythromycin showed significantly better effica-
cy among inpatient against MSSA (P < 0.05), and 
in the outpatient quinolones and TMP-SMX were 
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better (P < 0.05). For the MRSA, erythromycin and 
TMP-SMX showed significantly better anti-MRSA 
activity inpatient (P < 0.05), and in the outpatient, 
quinolones, gentamicin and rifampin were better 
(P < 0.05). The rest of the antimicrobials for both 
types of staphylococci showed no significant diffe-
rences (Figure 3)
Susceptibility rates to the other antimicrobials 
were evaluated among outpatient MRSA isolates, 
these were 74% for quinolones and 69% TMP/
SMX, respectively. An earlier study carried out in the 
Jordan University Hospital demonstrated that MRSA 
susceptibility to quinolones was 15%, clindamycin 
68%, and gentamicin 68%,respectively [35]. In the 
current study, a relatively higher susceptibility rates 
were observed for quinolones 74%, clindamycin 
56%, and gentamycin 94%, respectively. An older 
Saudi study from the 1980s [36] found imipenem 
to have had an excellent in vitro activity against 
MRSA isolates after vancomycin. Nevertheless, in 
this study the lack of sensitivity of MRSA isolates 
to β-lactam antibiotics exemplified by cephalospori-
nes and carbapenems is consistent with other more 
recent studies [7, 37 38]. Our finding showed that 
the susceptibility to imipenem was 0% among 35 
tested MRSA isolates. The rates of in vitro ineffec-
tive β-lactam for MRSA cases were 100% in this 
study, while up to decade earlier it was reported 
to be ineffective up to 78.7% by using empirical 
β-lactam prescriptions, and carried a poor progno-
sis [7, 39]. These results clearly demonstrated the 
escalating rates of resistance. 
The outcomes of patients treatment were analy-
zed for the vancomycin (MIC range 0.5-1 mg/L), they 
could not be analyzed for the other vancomycin MIC 
distributions as they were low in count. Treatment 
of patients infected with MRSA evidently pointed at 
worse outcomes (P = 0.018). The outcome of each 
patient when analyzed separately, was significant (P 
< 0.05) for improved and discharged, relapse-pro-
gression, ≤ 30-days readmission, infection related 
readmission, and all-cause of mortality. However, 
the result was not significant (P > 0.05) for dischar-
ged without improvement or after the switch to 
another antibiotic. 
Conclusion
The increasing MRSA rates leave limited treatment 
options. Evaluating 
S. aureus susceptibility to vancomycin with a mi-
nimum inhibitory concentration may help in predic-
ting outcomes, nonetheless, our study significantly 
demonstrated worse outcome with MRSA infection.
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